FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to modified interleukin-7 (IL-7) and a recombinant method for production thereof, and can be used in medicine for treating viral diseases selected from influenza, hepatitis B and hepatitis C, lymphocytopenia and cancer. Interleukin-7 is modified by bonding oligopeptide of 1–10 amino acid residues consisting of methionine, glycine or a combination thereof. Oligopeptide is not a single methionine. Modified IL-7 is used to produce a fused protein which additionally includes a domain which prolongs half-life of the fused protein.
EFFECT: invention enables to obtain stable modified IL-7 with high output.
36 cl, 11 dwg, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INCREASING NUMBER OF LYMPHOCYTES IN TUMOURS USING HYBRID PROTEIN IL-7 | 2020 |
|
RU2822396C1 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
| FUSED PROTEINS IL-7 | 2004 |
|
RU2369616C2 |
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
| RECOMBINANT YEAST TRANSFORMANT AND METHOD FOR OBTAINING WITH ITS USE OF Fc-FRAGMENT OF IMMUNOGLOBULIN | 2014 |
|
RU2664862C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| NOVEL IL-17-BINDING COMPOUNDS AND THEIR MEDICINAL APPLICATION | 2010 |
|
RU2550272C2 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| COMPLEXES OF ANTIBODIES WITH SOME CYTOKINES | 2000 |
|
RU2263118C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
